We have developed a first-in-class technology platform to create novel hybrid interferons, designed to deliver pleiotropic drug candidates engineered for reduced toxicity and improved efficacy.

Our platform can rationally design, select and develop novel hybrid interferon candidates, engineering highly specific proteins with multiple favourable attributes from natural IFNs.

Hybrid interferons have the potential to act on multiple targets and to modulate multiple facets of immunity in complex diseases, giving them a broader spectrum of activity compared with monoclonal antibodies or small molecules.

We have a growing body of pre-clinical data demonstrating the safety and efficacy profile of our hybrid interferon candidates.

All IP is wholly owned by ILC Therapeutics, including granted patents providing robust coverage of the Company’s candidates and their use, with coverage spanning across many territories including the EU and USA.

Pleiotropic effects of Hybrid IFNs